BioCentury | Feb 28, 2020
Distillery Therapeutics

Sudan ebolavirus glycoprotein-targeting mAbs to treat Sudan virus infection

DISEASE CATEGORY: Infectious disease INDICATION: Ebola A cocktail of two mAbs targeting the Sudan ebolavirus glycoprotein could treat infection by the virus. Identification of the antibody combination involved screening antibody libraries derived from mice and...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
BC Innovations | Dec 19, 2019
Distillery Therapeutics

Depleting platelets of inhibiting SOCS3 for atherosclerosis

DISEASE CATEGORY: Cardiovascular INDICATION: Atherosclerosis Platelet depletion or inhibition of SOCS3, a platelet-induced regulator of macrophage polarization, could treat atherosclerosis. Blood levels of SOCS3 RNA were higher in 61 women presenting with myocardial infarction (MI)...
BioCentury | Nov 22, 2019
Emerging Company Profile

Morphiex’s antisense take on CD47 aims for more than eating

Morphiex is breaking from the CD47 pack by undercutting the target’s expression on both tumor and immune cells instead of just blocking tumors’ “don’t eat me” signals via SIRPA. The company believes its antisense approach...
BioCentury | Nov 1, 2019
Emerging Company Profile

Tmunity: Manufacturing momentum for CAR and TCR therapies

Tmunity’s $75 million series B round will enable the company to keep advancing its CMC capabilities alongside its clinical and preclinical engineered CAR and TCR therapies for solid and blood tumors. Andreessen Horowitz (a16z) led...
BC Innovations | Oct 21, 2019
Emerging Company Profile

Verseau unveils tumor macrophage reprogramming strategy

Verseau is aiming to treat solid tumor patients who don't respond to T cell-targeting agents by reprogramming tumor-associated macrophages to make them immuno-stimulatory. Eight months after announcing a collaboration with 3SBio Inc. (HKSE:1530), Verseau Therapeutics...
BC Innovations | Oct 3, 2019
Emerging Company Profile

X-Vax: Bucking dogma in HSV vaccine development

Veering from the field’s focus on neutralizing antibodies, X-Vax is developing vaccines that elicit non-neutralizing antibodies that direct the immune system to kill infected cells. Its lead candidate is in preclinical development to prevent HSV...
BC Innovations | Sep 19, 2019
Product Development

Anokion puts liver to the test

Data presented Sept. 13 at a major multiple sclerosis meeting showcased the ability of Anokion’s liver targeting technology to induce immune tolerance. Armed with a fresh $40 million series B round, Anokion S.A. is developing...
BC Innovations | Aug 29, 2019
Distillery Therapeutics

Platelet transfusions for sepsis

DISEASE CATEGORY: Infectious disease INDICATION: Sepsis Platelet transfusions could treat sepsis by inducing monocytes to mature into proinflammatory macrophages. When co-cultured with platelets, activated monocytes were more likely to differentiate to M1 macrophages with proinflammatory...
BC Innovations | Aug 8, 2019
Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

Early clinical readouts for next-generation oncolytic viruses are hinting at high efficacy when combined with checkpoint inhibitors, and pharmas are off to the races to find the best pairings. After more than two decades of...
Items per page:
1 - 10 of 896